Login to Your Account

First in class? Beigene's BTK inhibitor yields positive phase I results

By Shannon Ellis
Staff Writer

Wednesday, December 9, 2015

SHANGHAI – Beigene Co. Ltd. has shared positive phase I results for BGB-3111, a targeted small-molecule BTK inhibitor to treat B-cell malignancies that Beigene execs believe has the potential to become first in class, beating out ibrutinib (Imbruvica, Pharmacyclics Inc./Johnson & Johnson).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription